FOLFIRINOXFolinic Acid, Fluorouracil, Irinotecan, and Oxaliplatin (cancer therapy)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
After an average three years of follow-up, almost 40 percent of the folfirinox patients were disease-free compared with about 20 percent who had the standard drug, Gemzar.
Not previously reported in the literature, our patient was treated with neoadjuvant chemotherapy (modified FOLFIRINOX).
Two patients sustained FOLFIRINOX for their adjuvant treatment, while to one patient gemcitabine/nab-paclitaxel was administered (Table 2).
Ychou et al., "FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer," The New England Journal of Medicine, vol.
Despite these limitations, the combination of gemcitabine and nab-paclitaxel became another first-line option for patients, particularly for the many patients who were deemed to be ineligible or unfit to receive the more potent FOLFIRINOX.
He was evaluated by the medical oncology service who recommended treatment with the FOLFIRINOX regimen.
Sanford et al., "Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a singlecentre, open-label, dose-finding, non-randomised, phase 1b trial," The Lancet Oncology, vol.
Several clinical trials have shown a modest survival benefit, such as FOLFIRINOX (oxaliplatin, irinotecan, leucovorin, and fluorouracil) and nab-paclitaxel plus gemcitabine [9, 10].
The introduction of combined therapies with irinotecan and/or oxaliplatin (FOLFOX, FOLFIRI, CapeOX, and FOLFIRINOX) showed significant improvement in disease-free survival and overall survival [303].
Regarding the type of induction chemotherapy, the investigator-initiated trial CONKO-007 [14] will help to clarify whether a more intense induction of 12 weeks chemotherapy with the use of FOLFIRINOX, which so far provides the best response rates for metastatic pancreatic cancer [15], has a clear effect in patients with LAPC and subsequent RT.
Till a recent report demonstrating good activity of oxaliplatin, irinotecan, and fluorofolate (FOLFIRINOX combination), gemcitabine is still the mainstay treatment.
A team of researchers was able to improve on gemcitabine by using instead a toxic combination of chemotherapy drugs (called FOLFIRINOX).